Home | BioBucks

Latest Editions of BioBucks

Jul 9, 2026

Thursday: 2 Phase III wins put Dysport in migraine's big leagues

Ipsen lands Phase III migraine data, Tarsus adds IRX-101, and FDA pauses new CRL disclosures.

Jul 8, 2026

Wednesday: First BAFF/APRIL inhibitor gets its FDA nod

Jul 7, 2026

Tuesday: Vertex swings $10B for Crinetics

Jul 6, 2026

Monday: Novartis pays $1.5B for ADC payload firepower

Jul 2, 2026

Thursday: Roche lands a KRAS G12C head-to-head win

Jul 1, 2026

Wednesday: Ipsen doubles down on rare disease

Jun 30, 2026

Tuesday: Epcoritamab cuts DLBCL progression risk ~60%

Jun 29, 2026

Monday: Ipsen's ~$1.75B myelofibrosis bet

Jun 26, 2026

Friday: Merck KGaA drops $11.3B on Bio-Techne

Jun 25, 2026

Thursday: Two FDA approvals before lunch — and a $10.6B tender clock